datopotamab deruxtecan
Sponsor Astrazeneca PLC · listed as AZN
datopotamab deruxtecan is a drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 5 forward catalysts for it — the nearest is a readout expected Jul 28, 2027 (day precision, medium confidence), tied to trial NCT06103864. That trial is in Phase 3 and currently recruiting, studying Breast Cancer. It appears across 17 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for datopotamab deruxtecan
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2027-07-28 | READOUT | medium | NCT06103864 |
| 2027-09-20 | READOUT | medium | NCT05629585 |
| 2027-11-01 | READOUT | medium | NCT05687266 |
| 2028-02-02 | READOUT | medium | NCT07205822 |
| 2028-03-21 | READOUT | medium | NCT06350097 |
Trials for datopotamab deruxtecan in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT04656652 | Phase 3 | Active, not recruiting | 2024-05-10 | Experimental | Daiichi Sankyo | Non-small Cell Lung Cancer |
| NCT05104866 | Phase 3 | Active, not recruiting | 2024-07-24 | Experimental | AstraZeneca | Breast Cancer |
| NCT05374512 | Phase 3 | Active, not recruiting | 2025-08-25 | Experimental | AstraZeneca | Breast Cancer |
| NCT06564844 | Phase 3 | Active, not recruiting | 2026-07-10 | Experimental | AstraZeneca | Non-small Cell Lung Cancer |
| NCT06417814 | Phase 3 | Recruiting | 2026-09-30 | Experimental | AstraZeneca | Metastatic Non-small Cell Lung Cancer |
| NCT06103864 catalyst | Phase 3 | Recruiting | 2027-07-28 | Experimental | AstraZeneca | Breast Cancer |
| NCT05629585 catalyst | Phase 3 | Active, not recruiting | 2027-09-20 | Experimental | AstraZeneca | Breast Cancer |
| NCT05687266 catalyst | Phase 3 | Active, not recruiting | 2027-11-01 | Experimental | AstraZeneca | NSCLC |
| NCT07205822 catalyst | Phase 3 | Recruiting | 2028-02-02 | Experimental | AstraZeneca | Breast Cancer |
| NCT06350097 catalyst | Phase 3 | Recruiting | 2028-03-21 | Experimental | AstraZeneca | Non-small Cell Lung Cancer |
| NCT06112379 | Phase 3 | Active, not recruiting | 2028-11-20 | Experimental | AstraZeneca | Breast Cancer |
| NCT07291037 | Phase 3 | Recruiting | 2029-01-29 | Experimental | AstraZeneca | Non-small Cell Lung Cancer (NSCLC) |
| NCT05555732 | Phase 3 | Active, not recruiting | 2029-05-11 | Experimental | Daiichi Sankyo | Metastatic Non Small Cell Lung Cancer |
| NCT07129993 | Phase 2/3 | Recruiting | 2029-06-01 | Experimental | Daiichi Sankyo | Urothelial Cancer; Bladder Cancer |
| NCT06357533 | Phase 3 | Recruiting | 2029-12-28 | Experimental | AstraZeneca | Non-Small Cell Lung Cancer |
| NCT05215340 | Phase 3 | Active, not recruiting | 2030-03-04 | Experimental | Daiichi Sankyo | Metastatic Non Small Cell Lung Cancer |
| NCT07720284 | Phase 3 | Recruiting | 2030-09-11 | Experimental | AstraZeneca | High-risk Muscle Invasive Urothelial Carcinoma |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More AZN catalysts